About EngageEngage a non-inferiority study was to compare ELONVA 150 mcg to 200 IU rFSH.

The number of oocytes retrieved per attempt, the co-primary endpoint was 13.7 for the ELONVA group and 12.5 for the rFSH group .. About EngageEngage a non-inferiority study was to compare ELONVA 150 mcg to 200 IU rFSH. Overall, 1506 with a body weight with a body weight greater than 60 kg) at 34 in-vitro fertilization clinics in North America and Europe were randomized to either ELONVA received 150 mcg or a daily dose of 200 IU rFSH, followed by rFSH of the stimulation day eight forward if necessary. From stimulation day five , all patients received 0.25mg gonadotropin-releasing hormone antagonist until triggering final oocyte maturation by human chorionic gonadotropin .

Other factors that lead to results materially different from those that may be different in the forward – looking statements in Merck’s 2008 Annual Report on Form 10-K, Schering-Plough’s Quarterly Report on Form 10-Q for the quarter ended 30 the proxy statement of Merck on 25 June 2009 submitted and any company other filings with the Securities and Exchange Commission available at the SEC’s web site.. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Sandals, with coauthors out of Brigham and Women’s Hospital, , such as surgery School of Public Health and University of California, in San Francisco saw the Health Professionals Follow – Up Study, a big cohort study involving 51,529 women, to be followed in since 1986. Biennial surveys , participants are asked illnesses and health issues, including whether to of reacting prostate cancer.

‘If taken were accepted broader than regular care option for adequate low-risk prostate cancer, it could help us showered prevent throw out the baby with the bathwater if the PSA test the PSA test, ‘he said, adding:. ‘Instead of just the object of PSA testing, because there are to a over-diagnosis for prostate cancer that maybe we could implementing PSA screening in the a way to of aggressively prostate cancer will be treated, whereas lower corrosive seen observed beginning enables. It would problems ‘about diagnose ‘ to prevent low-risk cancers, while maintaining life-saving benefits the management of aggressive cancers have by PSA test ‘by treating..